Contact this trialFirst, we need to learn more about you.
Hormone Therapy
RLY-2608 + Fulvestrant for Breast Cancer
Recruiting1 awardPhase 1
San Diego, California
This trial is designed to study the maximum tolerated dose, safety, and preliminary anti-cancer activity of RLY-2608 in patients with advanced solid tumors who have a PIK3CA mutation. The trial will have two parts: a dose escalation (Part 1) and a dose expansion (Part 2).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service